Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17808730 | 0.81 | PRKCQ (0.34) | CHEK1AKT2HSP90AA1MAPK1 | |
| SCHEMBL17808921 | 0.79 | USP1 (0.37) | MAPK1BRD4 | |
| SCHEMBL19365017 | 0.77 | KDM5A (0.37) | KDM5A | |
| SCHEMBL17808751 | 0.77 | RPS6KA3 (0.37) | KDM5A | |
| SCHEMBL17808905 | 0.76 | KDM5B (0.38) | KDM5AMKNK1MKNK2 | |
| SCHEMBL19361112 | 0.76 | TP53 (0.39) | HSP90AA1HSP90AB1BRD4 | |
| SCHEMBL17808756 | 0.76 | PTGS1 (0.36) | HSP90AA1HSP90AB1 | |
| SCHEMBL17808904 | 0.75 | TOP2A (0.36) | KDM5AMKNK1MKNK2 | |
| SCHEMBL17808725 | 0.74 | BRD4 (0.41) | HSP90AA1HSP90AB1BRD4 | |
| SCHEMBL17808902 | 0.74 | CCNE1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227292-B1 | 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS | ALTERITY THERAPEUTICS LTD (AU) | 2022-03-09 | — | — | EP | disclosed |
| US-20210230159-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2021-07-29 | — | — | US | disclosed |
| US-11008319-B2 | 4H-pyrido[1,2-a]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2021-05-18 | — | — | US | disclosed |
| US-20200317670-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2020-10-08 | — | — | US | disclosed |
| US-10738050-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190352301-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2019-11-21 | — | — | US | disclosed |
| US-10287285-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2019-05-14 | — | — | US | disclosed |
| US-20170267676-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20170267676-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2017-09-21 | — | — | US | disclosed |
| WO-2016086261-A1 | 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738050-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | KDM5A 3207/4885CHEK1 1474/4885AKT2 3604/4885 |
| US-20200317670-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | KDM5A 3207/4885CHEK1 1474/4885AKT2 3604/4885 |
| US-10287285-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | KDM5A 3207/4885CHEK1 1474/4885AKT2 3604/4885 |
| US-11008319-B2 | 4H-pyrido[1,2-a]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | KDM5A 3207/4885CHEK1 1474/4885AKT2 3604/4885 |
| US-20190352301-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | KDM5A 3207/4885CHEK1 1474/4885AKT2 3604/4885 |
| US-20210230159-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | KDM5A 3207/4885CHEK1 1474/4885AKT2 3604/4885 |
| US-20170267676-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | KDM5A 3207/4885CHEK1 1474/4885AKT2 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.